173 related articles for article (PubMed ID: 19155297)
1. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.
Memon AA; Jakobsen S; Dagnaes-Hansen F; Sorensen BS; Keiding S; Nexo E
Cancer Res; 2009 Feb; 69(3):873-8. PubMed ID: 19155297
[TBL] [Abstract][Full Text] [Related]
2. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
[TBL] [Abstract][Full Text] [Related]
3. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
[TBL] [Abstract][Full Text] [Related]
4. [
Traxl A; Beikbaghban T; Wanek T; Kryeziu K; Pirker C; Mairinger S; Stanek J; Filip T; Sauberer M; Kuntner C; Berger W; Langer O
Nucl Med Biol; 2017 Sep; 52():7-15. PubMed ID: 28575795
[TBL] [Abstract][Full Text] [Related]
5. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
[TBL] [Abstract][Full Text] [Related]
6. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain.
Petrulli JR; Sullivan JM; Zheng MQ; Bennett DC; Charest J; Huang Y; Morris ED; Contessa JN
Neoplasia; 2013 Dec; 15(12):1347-53. PubMed ID: 24403856
[TBL] [Abstract][Full Text] [Related]
8.
Jain A; Kameswaran M; Pandey U; Prabhash K; Sarma HD; Dash A
Bioorg Med Chem Lett; 2017 Oct; 27(19):4552-4557. PubMed ID: 28893469
[TBL] [Abstract][Full Text] [Related]
9. Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.
Bahce I; Smit EF; Lubberink M; van der Veldt AA; Yaqub M; Windhorst AD; Schuit RC; Thunnissen E; Heideman DA; Postmus PE; Lammertsma AA; Hendrikse NH
Clin Cancer Res; 2013 Jan; 19(1):183-93. PubMed ID: 23136193
[TBL] [Abstract][Full Text] [Related]
10. Radiosynthesis and biological evaluation of
Huang S; Han Y; Chen M; Hu K; Qi Y; Sun P; Wang M; Wu H; Li G; Wang Q; Du Z; Zhang K; Zhao S; Zheng X
Bioorg Med Chem Lett; 2018 Apr; 28(6):1143-1148. PubMed ID: 29486966
[TBL] [Abstract][Full Text] [Related]
11.
Pool M; Terwisscha van Scheltinga AGT; Kol A; Giesen D; de Vries EGE; Lub-de Hooge MN
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1328-1336. PubMed ID: 28315949
[TBL] [Abstract][Full Text] [Related]
12. Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET.
Abourbeh G; Itamar B; Salnikov O; Beltsov S; Mishani E
EJNMMI Res; 2015; 5():4. PubMed ID: 25853010
[TBL] [Abstract][Full Text] [Related]
13. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
[TBL] [Abstract][Full Text] [Related]
14. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
16. PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
Luo H; England CG; Graves SA; Sun H; Liu G; Nickles RJ; Cai W
J Nucl Med; 2016 Feb; 57(2):285-90. PubMed ID: 26541778
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
Abourbeh G; Dissoki S; Jacobson O; Litchi A; Ben Daniel R; Laki D; Levitzki A; Mishani E
Nucl Med Biol; 2007 Jan; 34(1):55-70. PubMed ID: 17210462
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Friess T; Scheuer W; Hasmann M
Clin Cancer Res; 2005 Jul; 11(14):5300-9. PubMed ID: 16033849
[TBL] [Abstract][Full Text] [Related]
19. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans.
Liu N; Li M; Li X; Meng X; Yang G; Zhao S; Yang Y; Ma L; Fu Z; Yu J
J Nucl Med; 2009 Feb; 50(2):303-8. PubMed ID: 19164239
[TBL] [Abstract][Full Text] [Related]
20. Further characterization of the epidermal growth factor receptor ligand 11C-PD153035.
Wang H; Yu JM; Yang GR; Song XR; Sun XR; Zhao SQ; Wang XW; Zhao W
Chin Med J (Engl); 2007 Jun; 120(11):960-4. PubMed ID: 17624262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
